Teva to buy U.S. drug developer Auspex Pharma for $3.5 billion-Reuters

Israel's Teva Pharmaceutical Industries said it would buy U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc for an equity value of $3.5 billion to boost its portfolio of treatments for the central nervous system.

DealsNorth AmericaUSBriefs